HC Wainwright Reiterates Buy Rating for Immunic (NASDAQ:IMUX)

Immunic (NASDAQ:IMUX)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a note issued to investors on Thursday, Benzinga reports. They currently have a $22.00 price target on the stock. HC Wainwright’s price objective suggests a potential upside of 80.48% from the stock’s current price.

Several other equities analysts also recently commented on the stock. Wall Street Zen upgraded shares of Immunic from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Wedbush started coverage on shares of Immunic in a research note on Monday, August 17th. They issued an “outperform” rating and a $45.00 price objective for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Immunic in a report on Wednesday, August 26th. LADENBURG THALM/SH SH upgraded shares of Immunic to a “strong-buy” rating in a research report on Wednesday, July 29th. Finally, Wolfe Research assumed coverage on shares of Immunic in a report on Friday, May 22nd. They set an “outperform” rating on the stock. Three research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Immunic currently has an average rating of “Buy” and a consensus target price of $47.25.

Immunic Trading Down 4.3%

Immunic stock opened at $12.19 on Thursday. The company has a market capitalization of $166.27 million, a price-to-earnings ratio of -2.78 and a beta of 1.41. Immunic has a 12 month low of $5.06 and a 12 month high of $17.43. The stock’s 50 day moving average is $14.81 and its 200-day moving average is $13.07.

Immunic (NASDAQ:IMUX) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.80) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.16) by $0.36. As a group, equities research analysts predict that Immunic will post -3.71 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Immunic

Several hedge funds have recently bought and sold shares of the company. CTC Alternative Strategies Ltd. acquired a new position in shares of Immunic in the 1st quarter valued at approximately $27,000. Qube Research & Technologies Ltd acquired a new stake in shares of Immunic during the 3rd quarter worth approximately $29,000. ADAR1 Capital Management LLC acquired a new stake in shares of Immunic during the 1st quarter worth approximately $33,000. Two Sigma Investments LP bought a new position in Immunic in the third quarter valued at approximately $52,000. Finally, Seven Fleet Capital Management LP bought a new position in Immunic in the fourth quarter valued at approximately $83,000. 51.82% of the stock is owned by institutional investors.

Immunic Company Profile

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.